Finance

BioNTech guides for worse-than-expected 2025 revenue decline

Published by Global Banking & Finance Review

Posted on March 10, 2025

1 min read

· Last updated: January 24, 2026

Add as preferred source on Google
BioNTech guides for worse-than-expected 2025 revenue decline
Global Banking & Finance Awards 2026 — Call for Entries

BioNTech Projects Greater Revenue Drop for 2025 Than Anticipated

FRANKFURT (Reuters) -German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ($1.85 billion) and 2.2 billion euros, prompting a decline in its share price.

The guidance compares with revenues of 2.75 billion euros reported for last year and with an average analyst estimate of about 2.5 billion for 2025, according to LSEG data.

The biotech firm's German traded stock was down 4.1% at 1110 GMT.

($1 = 0.9213 euros)

(Reporting by Ludwig Burger, editing by Thomas Seythal)

Key Takeaways

  • BioNTech projects 2025 revenues between 1.7 and 2.2 billion euros.
  • The forecast is below the 2.75 billion euros reported last year.
  • Analyst estimates for 2025 were around 2.5 billion euros.
  • BioNTech's stock fell 4.1% following the announcement.
  • The revenue decline impacts market perceptions and stock value.

Frequently Asked Questions

What revenue range did BioNTech project for 2025?
BioNTech projected its 2025 revenues to fall between 1.7 billion euros and 2.2 billion euros.
How does the 2025 revenue guidance compare to last year's figures?
The guidance for 2025 is a decline from the 2.75 billion euros reported for the previous year.
What was the market reaction to BioNTech's revenue guidance?
Following the announcement, BioNTech's stock was down 4.1% at 1110 GMT.
What was the average analyst estimate for BioNTech's 2025 revenue?
Analysts had an average estimate of about 2.5 billion euros for BioNTech's 2025 revenues.
What currency exchange rate was mentioned in the article?
The article noted that $1 is equivalent to 0.9213 euros.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category